In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses … Read more
The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second … Read more
April-June 2023 Net revenue for the period was SEK 344.4 million (231.9), an increase of 48.5%. Organic growth was 10.4%. Orders received for the period was SEK 319.3 million (260.9), an increase of 22.4%. Organic growth was 15.7%. EBITDA for the period was SEK 121.6 million (34.3) Profit/loss for the period was SEK 3.2 million … Read more
April-June 2022 Orders received for the period was SEK 260.9 million (122.8), an increase of 112.5 %. Organic growth was 22.3 %. Net revenue for the period was SEK 231.9 million (117.6), an increase of 97.1 %. Organic growth was 3.1 %. Adjusted EBITDA for the period was SEK 31.8 million (15.5) EBITDA for the … Read more
April – June 2021 Net revenue for the period was SEK 117.6 million (101.8) EBITDA for the period was SEK 15.8 million (15.1) EBITA for the period was SEK 13.3 million (13.1) Profit/loss for the period was SEK 0.1 million (8.3) Basic earnings per share for the period amounted to SEK 0.00 (0.07) Orders received … Read more